Evidence map›Paper›PMID 25186591›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2014

Current practices of screening for incident hepatitis C virus (HCV) infection among HIV-infected, HCV-uninfected individuals in primary care.

J Morgan Freiman, Wei Huang, Laura F White, Elvin H Geng, Christopher B Hurt, Lynn E Taylor, E Turner Overton, Edward R Cachay, Mari M Kitahata, Richard D Moore and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 1 country.

J Morgan FreimanHIV Epidemiology and Outcomes Research Unit, Section of Infectious Diseases, Boston Medical Center.
Wei HuangHIV Epidemiology and Outcomes Research Unit, Section of Infectious Diseases, Boston Medical Center.
Laura F WhiteDepartments of Biostatistics.
Elvin H GengSchool of Medicine, University of California, San Francisco.
Christopher B HurtInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill.
Lynn E TaylorDepartment of Medicine, Brown University, Providence, Rhode Island.
E Turner OvertonDivision of Infectious Diseases, University of Alabama at Birmingham School of Medicine.
Edward R CachayDepartment of Medicine, University of California, San Diego.
Mari M KitahataDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle.
Richard D MooreDivision of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland.
Benigno RodriguezDivision of Infectious Diseases and HIV Medicine, Case Western Reserve University, Cleveland, Ohio.
Kenneth H MayerFenway Institute, Fenway Health, Boston, Massachusetts.
Benjamin P LinasHIV Epidemiology and Outcomes Research Unit, Section of Infectious Diseases, Boston Medical Center Epidemiology, Boston University School of Public Health, Massachusetts.
Boston Medical Center · USBrown University · USCase Western Reserve University · USFenway Health · USJohns Hopkins University · USUniversity of Alabama at Birmingham · USUniversity of California, San Diego · USUniversity of California, San Francisco · USUniversity of North Carolina at Chapel Hill · USUniversity of Washington · US

Funding

Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
North American AIDS Cohorts on Collaboration and Design (NAACCORD)U01AI069918 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Keri Nicole Althoff, RICHARD Douglas MOORE · 2006 to 2026
$65.2M
Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH · 1998 to 2026
$51.7M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
Simulation Modeling to Improve HIV/HCV Screening, Treatment and CareR01DA031059 · NIDA · BOSTON MEDICAL CENTER · PI LINAS, BENJAMIN P. · 2012 to 2015
$2.1M
Home-Collected Blood Spots to Increase HIV Test Frequency among Young Black MSMK23MH099941 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HURT, CHRISTOPHER BROWNING · 2013 to 2017
$837k
NIAID NIH HHS P30 AI027767NIAID NIH HHS P30AI027767NIAID NIH HHS P30 AI042853NIAID NIH HHS R24 AI067039NIAID NIH HHS R24AI067039NIAID NIH HHS U01 AI069918NIDA NIH HHS R01 DA031059NIDA NIH HHS R01DA031059NIDA NIH HHS U01 DA036935NIMH NIH HHS K23 MH099941NIMH NIH HHS K23MH099941
6 · The paper itself

Abstract

backgroundHuman immunodeficiency virus (HIV)-infected, hepatitis C virus (HCV)-uninfected patients are at risk for incident HCV infection, but little is known about screening practices for incident HCV among HIV-infected individuals in HIV primary care clinics.

methodsWe used data from the Center for AIDS Research Network of Integrated Clinical Systems (CNICS) to investigate historical trends in screening for incident HCV infection among HIV-infected patients who were HCV-uninfected at enrollment in care. We used descriptive measures and Poisson regression to identify factors associated with screening for HCV infection (using HCV antibody or RNA), performed temporal analyses to assess changes in screening over time, and investigated the frequency with which elevated alanine aminotransferase (ALT) levels were followed by diagnostic HCV testing.

resultsAmong 17 090 patients registered at CNICS sites between 2000 and 2011, 14 534 (85%) received HCV antibody screening within 3 months of enrolling in care, and 9077 met all of the inclusion criteria. Only 55.6% ever received additional HCV screening. HCV screening increased over time, but not uniformly at all sites. Only 26.7% of first-time ALT elevations to >100 IU/L were followed up within 12 months by HCV antibody or RNA testing.

conclusionsAlthough most HIV-infected patients were screened for prevalent HCV infection at enrollment in care, only half who were HCV uninfected were screened again. Screening varied between sites, even when controlling for demographics and risk behaviors. Patients with new ALT elevations to >100 IU/L were seldom assessed for incident HCV infection. Guidelines are needed to help HIV providers know whom to screen, how frequently to screen, and which screening test to use.

Indexed as

AdultCoinfectionFemaleHepatitis CHepatitis C AntibodiesHIV InfectionsHumansMaleMiddle AgedRetrospective StudiesYoung AdultHepatitis C Antibodieshepatitis CHIVincidencemen who have sex with menscreening

Identifiers

PMID25186591
PMCPMC4311177
OpenAlexW2141332277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.